Deep Learning From Routine Histology Improves Risk Stratification for Biochemical Recurrence in Prostate Cancer

• URL: http://arxiv.org/abs/2603.14187v1
• Date: Sun, 15 Mar 2026 02:22:38 GMT
• Title: Deep Learning From Routine Histology Improves Risk Stratification for Biochemical Recurrence in Prostate Cancer
• Abstract summary: We present a deep learning-based biomarker that predicts continuous, patient-specific risk of biochemical recurrence after radical prostatectomy.<n>When integrated with the CAPRA-S clinical risk score, the deep learning risk score consistently improved discrimination for BCR.
• Score: 2.499184782167909
• License: http://creativecommons.org/licenses/by-sa/4.0/
• Abstract: Accurate prediction of biochemical recurrence (BCR) after radical prostatectomy is critical for guiding adjuvant treatment and surveillance decisions in prostate cancer. However, existing clinicopathological risk models reduce complex morphology to relatively coarse descriptors, leaving substantial prognostic information embedded in routine histopathology underexplored. We present a deep learning-based biomarker that predicts continuous, patient-specific risk of BCR directly from H&E-stained whole-slide prostatectomy specimens. Trained end-to-end on time-to-event outcomes and evaluated across four independent international cohorts, our model demonstrates robust generalization across institutions and patient populations. When integrated with the CAPRA-S clinical risk score, the deep learning risk score consistently improved discrimination for BCR, increasing concordance indices from 0.725-0.772 to 0.749-0.788 across cohorts. To support clinical interpretability, outcome-grounded analyses revealed subtle histomorphological patterns associated with recurrence risk that are not captured by conventional clinicopathological risk scores. This multicohort study demonstrates that deep learning applied to routine prostate histopathology can deliver reproducible and clinically generalizable biomarkers that augment postoperative risk stratification, with potential to support personalized management of prostate cancer in real-world clinical settings.

Related papers

• Towards Precision Therapy in Hepatocellular Carcinoma: A Clinical-Reasoning LLM for Risk Stratification and Treatment Guidance [69.07885031885303]
  We present HCC-STAR (Hepatocellular Carcinoma Staging, Treatment And pRognosis), a clinically aligned large language model.<n>It outputs risk score-based staging, ranked guideline-consistent treatments with evidence-based rationales, and individualized survival estimates.<n>In a multi-center cohort of 6,668 patients from 12 hospitals in China, HCC-STAR achieved state-of-the-art performance in treatment recommendation and risk stratification.
  arXiv  Detail & Related papers  (2026-07-09T15:33:08Z)
• Decoding Future Risk: Deep Learning Analysis of Tubular Adenoma Whole-Slide Images [2.0049131811804144]
  Colorectal cancer (CRC) remains a significant cause of cancer-related mortality.<n>A notable portion of patients initially diagnosed with low-grade adenomatous polyps will still develop CRC later in life.<n>This study investigates whether machine learning algorithms, specifically convolutional neural networks (CNNs), can detect subtle histological features in whole-slide images.
  arXiv  Detail & Related papers  (2026-02-09T20:00:04Z)
• AI-based Prediction of Biochemical Recurrence from Biopsy and Prostatectomy Samples [0.012216782333971603]
  Biochemical recurrence (BCR) after radical prostatectomy is a surrogate marker for aggressive prostate cancer.<n>We trained an AI-based model on diagnostic prostate biopsy slides to predict patient-specific risk of BCR.
  arXiv  Detail & Related papers  (2026-01-28T20:33:15Z)
• Deep Pathomic Learning Defines Prognostic Subtypes and Molecular Drivers in Colorectal Cancer [16.930050030905782]
  The TDAM-CRC predictive performance significantly outperformed the conventional clinical staging system and multiple state-of-the-art models.<n>The TDAM-CRC risk score was confirmed as an independent prognostic factor in multivariable analysis.<n>We identified and validated Mitochondrial Ribosomal Protein L37 (MRPL37) as a key hub gene linking deep pathomic features to clinical prognosis.
  arXiv  Detail & Related papers  (2025-11-19T03:19:43Z)
• TopoTxR: A topology-guided deep convolutional network for breast parenchyma learning on DCE-MRIs [49.69047720285225]
  We propose a novel topological approach that explicitly extracts multi-scale topological structures to better approximate breast parenchymal structures. We empirically validate emphTopoTxR using the VICTRE phantom breast dataset. Our qualitative and quantitative analyses suggest differential topological behavior of breast tissue in treatment-na"ive imaging.
  arXiv  Detail & Related papers  (2024-11-05T19:35:10Z)
• Computational Pathology for Accurate Prediction of Breast Cancer Recurrence: Development and Validation of a Deep Learning-based Tool [0.40205899806543505]
  Deep-BCR-Auto is a deep learning-based computational pathology approach that predicts breast cancer recurrence risk. Our methodology was validated on two independent cohorts. Deep-BCR-Auto demonstrated robust performance in stratifying patients into low- and high-recurrence risk categories.
  arXiv  Detail & Related papers  (2024-09-23T19:22:06Z)
• Regression-based Deep-Learning predicts molecular biomarkers from pathology slides [40.24757332810004]
  We developed and evaluated a new self-supervised attention-based weakly supervised regression method that predicts continuous biomarkers directly from images. Using regression significantly enhances the accuracy of biomarker prediction, while also improving the interpretability of the results over classification. Our open-source regression approach offers a promising alternative for continuous biomarker analysis in computational pathology.
  arXiv  Detail & Related papers  (2023-04-11T11:43:51Z)
• Penalized Deep Partially Linear Cox Models with Application to CT Scans of Lung Cancer Patients [42.09584755334577]
  Lung cancer is a leading cause of cancer mortality globally, highlighting the importance of understanding its mortality risks to design effective therapies. The National Lung Screening Trial (NLST) employed computed tomography texture analysis to quantify the mortality risks of lung cancer patients. We propose a novel Penalized Deep Partially Linear Cox Model (Penalized DPLC), which incorporates the SCAD penalty to select important texture features and employs a deep neural network to estimate the nonparametric component of the model.
  arXiv  Detail & Related papers  (2023-03-09T15:38:16Z)
• Mixed Supervision of Histopathology Improves Prostate Cancer Classification from MRI [0.9395521049323435]
  Non-invasive prostate cancer detection from MRI has the potential to revolutionize patient care. We present an MRI-based deep learning method for predicting clinically significant prostate cancer applicable to a patient population.
  arXiv  Detail & Related papers  (2022-12-13T02:34:57Z)
• Exploiting segmentation labels and representation learning to forecast therapy response of PDAC patients [60.78505216352878]
  We propose a hybrid deep neural network pipeline to predict tumour response to initial chemotherapy. We leverage a combination of representation transfer from segmentation to classification, as well as localisation and representation learning. Our approach yields a remarkably data-efficient method able to predict treatment response with a ROC-AUC of 63.7% using only 477 datasets in total.
  arXiv  Detail & Related papers  (2022-11-08T11:50:31Z)
• MIA-Prognosis: A Deep Learning Framework to Predict Therapy Response [58.0291320452122]
  This paper aims at a unified deep learning approach to predict patient prognosis and therapy response. We formalize the prognosis modeling as a multi-modal asynchronous time series classification task. Our predictive model could further stratify low-risk and high-risk patients in terms of long-term survival.
  arXiv  Detail & Related papers  (2020-10-08T15:30:17Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.